OncologyTube

05/01/2026

🧬 Cracking the Immunotherapy Code: Is Path-IO the New Gold Standard?Predicting which patients will truly benefit from immunotherapy remains one of the biggest challenges in NSCLC. While PD-L1 is the current standard, it doesn't tell the whole story. At AACR 2026, Rukhmini Bandyopadhyay, PhD from MD Anderson Cancer Center unveiled Path-IO—a biology-informed AI framework that transforms routine H&E slides into powerful Tissue Habitat Maps. Why Path-IO is a Game-Changer:Beyond the "Black Box": Unlike typical AI, Path-IO is biologically interpretable, mapping tumor-immune interactions at the cellular scale. Global Scalability: It uses routine H&E slides, making precision oncology accessible worldwide without expensive multiplexing. Proven Accuracy: Validated across >1,000 cases with an accuracy of 86.6% at MD Anderson. Treatment Guidance: Helps clinicians stratify patients for IO-monotherapy vs. IO-chemo combinations. Watch the full presentation and access the data here:👉 https://oncologytube.com/path-io-ai-nsclc-immunotherapy-prediction/

04/16/2026

🚨 New Research Alert: Treating PE in Cancer Patients 🚨
https://oncologytube.com/pe-cancer-treatment-gap/

Cancer patients face a 4-7x higher risk of venous thrombosis, but managing pulmonary embolism (PE) is a major challenge due to high bleeding risks. 🩸

Dr. Maria Molina from Desert Valley Hospital discusses her latest study on advanced interventions—such as catheter-directed thrombolysis—and why treatment must be tailored for high-risk groups, especially those with GI cancers. 🏥

Watch the full presentation here: [Link] 🎥

Research shows 92% of cancer patients with PE receive only blood thinners. Are bleeding risks preventing necessary advanced interventions?

04/16/2026

Traditionally, tumor grade has long been a marker for breast cancer prognosis, but genomic insights are changing the standard of care.

Dr. Erin Cobain discusses how the 70-gene MammaPrint assay provides a more refined risk stratification, specifically identifying High Risk 2 tumors that may benefit most from anthracyclines and neoadjuvant immunotherapy.

Watch the full interview and see the latest updates on the SWOG S2206 clinical trial here: https://oncologytube.com/mammaprint-high-risk-immunotherapy-standard/

Dr. Erin Cobain explains how MammaPrint High-Risk genomic tests improve breast cancer prognosis and treatment.

04/13/2026

Celebrating 35 Years of Excellence in Oncology 🎗️

https://oncologytube.com/moasc-2026-award-ceremony-highlights/

It was an honor to celebrate MOASC’s 35th anniversary by recognizing the incredible talent in our Southern California medical community. This year's ceremony was a powerful mix of looking back at our history and looking forward to the future.5

Highlights included:

Huge congratulations to Dr. Arjun Gower, winner of the Carey Presant Young Investigator Award for his groundbreaking work on lung cancer biomarkers. 🫁

The Warren Fong Advocacy Award: Presented to Dr. Amy Cummings for her vital work addressing the lung cancer screening crisis in California.

Mentorship Insights: Our panel of experts shared candid lessons on avoiding burnout, the importance of "living in the present," and why curiosity is the engine of research.

Next Gen Leaders: We celebrated outstanding poster presentations in translational and clinical research from residents and fellows across the state.

We are so grateful to our sponsors and members for fostering the next generation of oncologists. Let’s keep pushing the boundaries of care together!

Explore the highlights of the MOASC 2026 Annual Award Ceremony, featuring Dr. Arjun Gower, the Warren Fong Advocacy Award, and expert career insights.

04/10/2026

🎉 Congratulations to Dr. Arjan Gower, MD from UCLA Health!

He is the proud recipient of the $25,000 Cary Presant Young Investigator Award at the MOASC 2026 Annual Meeting in Newport Beach.

Dr. Gower’s research aims to develop a novel blood-based methylome signature to better predict how patients respond to datopotamab deruxtecan (Dato-DXd) in advanced lung cancer.

We’re grateful to AVEO Oncology for their generous sponsorship of this award and to MOASC for continuing to invest in the future of oncology.

Watch the full heartfelt ceremony video on OncologyTube
👉 https://oncologytube.com/dr-arjan-gower-cary-presant-young-investigator-award-moasc-2026/

Dr. Arjan Gower wins the Cary Presant Young Investigator Award at MOASC 2026. The $25,000 AVEO-sponsored grant supports his lung cancer biomarker research.

04/10/2026

Can You Safely Skip Anthracycline in Early HR+ HER2- Breast Cancer?

New FLEX trial data answers the question clearly:

MammaPrint High Risk 2 + BluePrint Luminal B patients achieved 100% 3-year invasive disease-free survival with ACT versus only 89.3% with TC — delivering a 10.7% absolute iDFS benefit.

High Risk 1 patients did equally well with TC alone.

Dr. Joyce A. O’Shaughnessy, Principal Investigator of the FLEX study, breaks down exactly how MammaPrint + BluePrint now guide anthracycline decisions — and how the 2026 NCCN Guidelines have already incorporated these results.

Watch the full expert discussion and see how this changes daily practice:

https://oncologytube.com/mammaprint-blueprint-anthracycline-flex-study-nccn/

What are your thoughts on de-escalating anthracycline in High Risk 1 patients?

FLEX trial data: MammaPrint High Risk 2 + BluePrint Luminal B patients gain 10.7% absolute iDFS benefit with anthracycline (100% vs 89.3%). High Risk 1 do well with TC. NCCN 2026 update.

04/07/2026

🔥 Major 2026 Cancer Breakthroughs from the MOASC Summit!

Dr. Joshua Cohen, Gynecologic Oncologist at City of Hope, breaks down the most exciting advances presented this year:

✅ ctDNA testing that can spot breast cancer recurrence years before imaging — allowing earlier, life-saving changes in treatment
✅ Explosive progress with tri-specific antibodies and next-generation CAR-T in multiple myeloma
✅ PARP inhibitors being used earlier in prostate cancer for BRCA-mutated patients with big survival gains
✅ Growing attention on therapy-induced senescence and how we can protect cancer survivors from accelerated aging

Watch the full interview with Dr. Cohen here:

👉 https://oncologytube.com/2026-cancer-breakthroughs-dr-joshua-cohen-moasc/

Which of these breakthroughs excites you the most? Drop your thoughts below! 👇

Dr. Joshua Cohen shares 2026 cancer breakthroughs from MOASC: ctDNA in breast cancer, tri-specific antibodies + CAR-T in myeloma, and more.

04/03/2026

🚨 Major 2026 Colorectal Cancer Updates Are Here!

Dr. Jason A. Zell from UC Irvine just presented the latest practice-changing data from the MOASC Annual Meeting.

In this clear and concise video, he covers:

• The ATOMIC trial – showing real survival benefit with immunotherapy in adjuvant MSI-high colon cancer
• BREAKWATER trial – new first-line options for BRAF V600E metastatic disease
• CHALLENGE trial – why structured exercise should now be standard for colon cancer survivors

Plus, he shares practical takeaways on biomarker testing and treatment sequencing.

👉 Watch the full update here:
https://oncologytube.com/colorectal-cancer-updates-2026-atomic-breakwater-commit-challenge-trials-jason-zell

Which of these trials do you think will impact your practice the most? Drop a comment below! 👇

Colorectal cancer updates 2026: Dr. Jason Zell covers key results from ATOMIC, BREAKWATER, COMMIT, and CHALLENGE trials.

03/31/2026

Is PARP inhibitor + ARPI combination therapy the new first-line standard for BRCA-mutated metastatic prostate cancer?
In this timely interview from MOASC 2026, Dr. Charles B. Nguyen from City of Hope Orange County shares practical insights on:

Which patients benefit most (BRCA1/2 vs ATM)
Key data from PROpel, MAGNITUDE, TALAPRO-2 & AMPLITUDE
When to sequence PARP inhibitors
Genetic testing recommendations
Important toxicities to manage

Watch the full expert interview and read the detailed companion article:
👉 https://oncologytube.com/parp-inhibitors-prostate-cancer-moasc-2026-charles-nguyen/
What are your thoughts on moving PARP inhibitors earlier in the treatment paradigm? Drop a comment below!

When to start PARP inhibitors in prostate cancer with ARPI for BRCA-mutated cases? Dr. Charles Nguyen shares MOASC 2026 insights.

03/27/2026

💡 What if one short course of a supplement found in strawberries could reverse frailty in breast cancer survivors after chemo?
New data from the TROFFI and PROFFI trials presented at MOASC 2026 says YES.
Dr. Mina Sedrak from UCLA shares groundbreaking research on how targeting therapy-induced senescence with the natural senolytic fisetin improved physical function, grip strength, and quality of life in survivors.
P16 biomarker clues, the 6-minute walk test as the key endpoint, and a bold new direction for survivorship care.
This could change everything for patients.
👉 Watch the full interview + read the complete article with slides:
https://oncologytube.com/can-fisetin-reverse-frailty-breast-cancer-survivors-moasc-2026
Tag a survivor or oncology friend who needs to see this! ❤️

New MOASC 2026 data: Fisetin can reverse frailty in breast cancer survivors. Dr. Mina Sedrak shares PROFY & TROPHY results on senescence.

03/26/2026

💥 The comeback no one saw coming in myeloma! 💥

Belantamab mafodotin is officially back in a big way for 2026 — and Dr. Amrita Krishnan from City of Hope just spilled all the details live from MOASC 2026.

Watch the full interview and stats here:
https://oncologytube.com/belantamab-comeback-myeloma-trends-2026-dr-krishnan/

In this interview she reveals:
• Why belantamab is now a strong option even in early relapse
• Bispecifics finally moving earlier in treatment
• Brand-new trispecific antibodies showing incredible early results
• “Off-the-shelf” in vivo CAR-T that could change everything
• A new toxicity to watch for (IEC colitis)

If you or someone you know is dealing with multiple myeloma, this is the update you don’t want to miss.

Tag a colleague or hematologist who needs to see this! 👇

Belantamab mafodotin comeback in 2026. Dr. Amrita Krishnan on myeloma trends 2026, earlier bispecifics & in vivo CAR-T at MOASC.